Evidence map›Paper›PMID 40824895›Full record

ArticlePloS one2025

Clinical experience of genome-wide non-invasive prenatal testing as a first-tier screening test in a cohort of 59,771 pregnancies.

Jianxin Zhen, Liting Zhang, Huilin Wang, Xi Chen, Weihong Wang, Lili Li, Quanfu Zhang

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jianxin ZhenCentral Laboratory, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, Guangdong Province, China.ORCID https://orcid.org/0000-0003-4899-4422
Liting ZhangCentral Laboratory, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, Guangdong Province, China.
Huilin WangCentral Laboratory, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, Guangdong Province, China.
Xi ChenCentral Laboratory, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, Guangdong Province, China.
Weihong WangCentral Laboratory, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, Guangdong Province, China.
Lili LiDepartment of Obstetrics, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, Guangdong Province, China.
Quanfu ZhangCentral Laboratory, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, Guangdong Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveGenome-wide non-invasive prenatal testing (GW-NIPT) for prenatal screening has been widely implemented. However, the related clinical data is still insufficient. Here, we evaluated the clinical performance of GW-NIPT as a first-tier screening test for detecting fetal aneuploidy and copy number variation (CNV).

methodsThe study included 59,877 pregnant women who underwent GW-NIPT at Shenzhen Baoan Women's and Children's Hospital, China, from November 2017 to May 2021. NIPT was performed on the BGISEQ-500 platform. Fetal karyotype analysis, chromosomal microarray analysis (CMA) and fluorescence in situ hybridization were used for invasive diagnostic procedures, and postnatal outcomes were collected.

resultsAmong 59,877 pregnant women who underwent GW-NIPT, 59,771 were successfully tested. Of these, 499 (0.83%) were identified with 504 high-risk fetal chromosomal abnormalities, including 5 cases each carrying two distinct abnormalities. Follow-up analysis demonstrated that GW-NIPT sensitivity exceeded 97% for fetal aneuploidies and was 63.6% for CNV (≥5 Mb). The positive predictive values for T21, T18, T13, sex chromosome aneuploidy, rare autosomal aneuploidy, and CNV (≥5 Mb) were calculated as 83.1%, 25.8%, 10.3%, 51.9%, 2.0%, and 33.9%, respectively. For confirmed fetal mosaicism, the detection rate of NIPT was 70.6%, which was consistent with that of CMA (70.6%).

conclusionsGW-NIPT has high sensitivity in screening fetal aneuploidy and moderate clinical utility in detecting CNV and fetal mosaicism, demonstrating that GW-NIPT holds significant application value in current and future prenatal screening procedures.

Indexed as

Chromosome DisordersNoninvasive Prenatal TestingPrenatal DiagnosisAdultAneuploidyChinaChromosome AberrationsDNA Copy Number VariationsFemaleGenetic TestingHumansIn Situ Hybridization, FluorescenceKaryotypingPregnancy

Identifiers

PMID40824895
PMCPMC12360580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.